India's Hetero gets emergency use nod to make Roche's COVID-19 drug - Reuters India

serongyu.blogspot.com

BENGALURU, Sept 6 (Reuters) - Indian drug developer Hetero said on Monday it has received emergency use approval from the country's health authorities to make a generic version of Roche Holding AG's (ROG.S) COVID-19 drug.

Hetero expects to make the treatment, tocilizumab, available in India by the end of the month under the brand name Tocira. Tocilizumab has been facing a global shortage as the highly contagious COVID-19 Delta variant drives up cases in several countries.

COVID-19 cases in India have declined from levels hit during the second wave in April and May, although health experts believe that the country should brace for a third wave by October.

Roche's blockbuster arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation. read more

Tocira will be made by Hetero's unit at its Hyderabad facility.

Hetero, which makes COVID-19 treatments like remdesivir and favipiravir, had also sought emergency approval for Merck's COVID-19 drug molnupiravir in July. read more

Reporting by Shivani Singh in Bengaluru; Editing by Devika Syamnath

Our Standards: The Thomson Reuters Trust Principles.

Adblock test (Why?)

"use" - Google News
September 06, 2021 at 03:24PM
https://ift.tt/3n6UE8n

India's Hetero gets emergency use nod to make Roche's COVID-19 drug - Reuters India
"use" - Google News
https://ift.tt/2P05tHQ
https://ift.tt/2YCP29R

Bagikan Berita Ini